Headquarters: Lexington, Massachusetts, United States
52 week low:0.8
52 week high:8.95
Next ER:August 25, 2021 Before Market Opens
Top Stories (XBIO)
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART?, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient?s malignant tumor cells for the treatment of B-cell lymphomas. XCART? has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Talk about Xenetic Biosciences, Inc. below in comments section below.
Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.